381 related articles for article (PubMed ID: 29031068)
21. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
22. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
[TBL] [Abstract][Full Text] [Related]
23. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
[TBL] [Abstract][Full Text] [Related]
24. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
[TBL] [Abstract][Full Text] [Related]
25. Cis,cis,trans-[Pt
Ravera M; Gabano E; Zanellato I; Rangone B; Perin E; Ferrari B; Bottone MG; Osella D
Dalton Trans; 2021 Mar; 50(9):3161-3177. PubMed ID: 33595015
[TBL] [Abstract][Full Text] [Related]
26. Alternative mechanism of action of the DNP Pt
Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
[TBL] [Abstract][Full Text] [Related]
27. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors.
Shen H; Ge Y; Wang J; Li H; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2021 Sep; 47():128169. PubMed ID: 34091044
[TBL] [Abstract][Full Text] [Related]
29. Zap-Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat.
Troelsen KS; Calder EDD; Skwarska A; Sneddon D; Hammond EM; Conway SJ
ChemMedChem; 2021 Dec; 16(24):3691-3700. PubMed ID: 34259396
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
[TBL] [Abstract][Full Text] [Related]
31. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
32. Novel 4,5-dihydrospiro[benzo[c]azepine-1,1'-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation.
Li S; Li XY; Zhang TJ; Zhu J; Liu KL; Wang DP; Meng FH
Bioorg Chem; 2021 Jun; 111():104840. PubMed ID: 33780687
[TBL] [Abstract][Full Text] [Related]
33. Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor.
Rubio-Ruiz B; Weiss JT; Unciti-Broceta A
J Med Chem; 2016 Nov; 59(21):9974-9980. PubMed ID: 27786474
[TBL] [Abstract][Full Text] [Related]
34. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
35. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
36. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
[TBL] [Abstract][Full Text] [Related]
37. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
38. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
39. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule.
Zhao Q; Lan T; Su S; Rao Y
Chem Commun (Camb); 2019 Jan; 55(3):369-372. PubMed ID: 30540295
[TBL] [Abstract][Full Text] [Related]
40. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
